Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:49 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 49 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Extended-Release Bupropion Hydrochloride Clear all
Completed Phase 3 Interventional Results available

Smoking-Cessation and Stimulant Treatment (S-CAST)

NCT01077024
View directory record Official record
Conditions
Cocaine Dependence, Methamphetamine Dependence, Nicotine Dependence
Interventions
Smoking-cessation treatment
Other
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
538 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
12
States / cities
Tucson, Arizona • Rancho Cucamonga, California • Tarzana, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2021 · Synced Oct 4, 2026, 5:49 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Safety and PK Study of BICX104 With or Without Bupropion Compared to Vivitrol

NCT07269873
View directory record Official record
Conditions
Healthy Adult Male and Female Volunteers
Interventions
BICX104 naltrexone implantable pellet, Bupropion 150 mg XL, Naltrexone (depot)
Drug
Lead sponsor
BioCorRx Pharmaceuticals Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional

Wellbutrin XL, Major Depressive Disorder and Breast Cancer

NCT00234195
View directory record Official record
Conditions
Breast Cancer, Major Depressive Disorder
Interventions
bupropion extended release (Wellbutrin XL)
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 17, 2007 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Zonisamide/Bupropion Effects on Switching to Electronic Cigarettes

NCT04388319
View directory record Official record
Conditions
Smoking Cessation
Interventions
Zonisamide, Bupropion, Halo G6 e-cigarette
Drug · Other
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 13, 2022 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effect of Naltrexone and Bupropion Extended-Release Combination on Cardiac Repolarization in Healthy Participants

NCT02735603
View directory record Official record
Conditions
Heart Repolarization
Interventions
Naltrexone HCl/bupropion HCl, Placebo, Moxifloxacin
Drug · Other
Lead sponsor
Orexigen Therapeutics, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

NCT02400346
View directory record Official record
Conditions
Major Depression Disorder
Interventions
Adjunct brexpiprazole, ADT
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
65 Years and older
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
13
States / cities
Arcadia, California • Miami, Florida • Orlando, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Active, not recruiting Phase 3 Interventional

Trial of Naltrexone/Bupropion for the Treatment of Methamphetamine Use Disorder

NCT06233799
View directory record Official record
Conditions
Methamphetamine-dependence, Methamphetamine Abuse
Interventions
extended-release naltrexone (XR-NTX), extended release bupropion (BUP-XL) tablets (BUP-XL), iPLB, oPLB
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 65 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
11
States / cities
Little Rock, Arkansas • Los Angeles, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Results available

Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder

NCT03078075
View directory record Official record
Conditions
Methamphetamine Use Disorder
Interventions
Naltrexone: Vivitrol®, Placebo (PLB) Injectable, Bupropion: Wellbutrin XL®, Placebo (PLB) Oral
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
403 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Minneapolis, Minnesota + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

The Effects of Combination Zonisamide and Bupropion on Switching to an Electronic Cigarette

NCT05205811
View directory record Official record
Conditions
Smoking Cessation
Interventions
Bupropion, Zonisamide, Placebo bupropion, Placebo zonisamide, E-cigarette
Drug · Other
Lead sponsor
Rose Research Center, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
2
States / cities
Charlotte, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Recruiting Phase 4 Interventional

Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial

NCT04604509
View directory record Official record
Conditions
Cigarette Smoking-Related Carcinoma
Interventions
Bupropion Hydrochloride Controlled-release, Nicotine Replacement, Questionnaire Administration, Tobacco Cessation Counseling, Varenicline
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2,010 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional

Lethargic Depression Study

NCT00064467
View directory record Official record
Conditions
Epilepsy, Major Depressive Disorder (MDD)
Interventions
Extended-release bupropion (HCl)
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
24
States / cities
Beverly Hills, California • Sherman Oaks, California • Temecula, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 1 Interventional

Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions

NCT01046214
View directory record Official record
Conditions
Depressive Disorder
Interventions
Bupropion HCl
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
25 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
2
States / cities
Culver City, California • Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2015 · Synced Oct 4, 2026, 5:49 AM EDT
Terminated Phase 4 Interventional Results available

EMI-EHP Weight Management and Type 2 Diabetes Pragmatic Trial

NCT04531176
View directory record Official record
Conditions
Type 2 Diabetes, Obesity
Interventions
Weight Management Program (WMP), Traditional care, Phentermine / Topiramate Extended Release Oral Capsule, naltrexone/bupropion extended-release, liraglutide 3.0 mg, Orlistat
Other · Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Bupropion for the Prevention of Postpartum Smoking Relapse

NCT04098874
View directory record Official record
Conditions
Postpartum Smoking Relapse
Interventions
Bupropion Extended Release Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

Optimizing Outcomes of Treatment-Resistant Depression in Older Adults

NCT02960763
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder, Treatment-Refractory Depression, Late Life Depression, Geriatric Depression
Interventions
Aripiprazole Augmentation, Bupropion Augmentation, Switch to bupropion, Lithium Augmentation, Switch to nortriptyline
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
60 Years and older
Enrollment
742 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
4
States / cities
Los Angeles, California • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2024 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional

Prevention of Seasonal Affective Disorder

NCT00046241
View directory record Official record
Conditions
Seasonal Affective Disorder
Interventions
Extended-release bupropion hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
43
States / cities
Anchorage, Alaska • Hamden, Connecticut • Boise, Idaho + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-drug Interaction Study of Clemizole (EPX-100) in Healthy Participants

NCT07824193
View directory record Official record
Conditions
Drug Drug Interaction
Interventions
EPX-100, Itraconazole, Phenytoin, Omeprazole, Midazolam, Bupropion
Drug
Lead sponsor
Epygenix
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Bupropion for Fatigue in End-stage Kidney Disease Patients on Hemodialysis

NCT06609343
View directory record Official record
Conditions
End Stage Renal Disease, Fatigue
Interventions
Bupropion Hydrochloride 150 MG
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
25 Years to 74 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Not yet recruiting Phase 1Phase 2 Interventional

A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients

NCT07398404
View directory record Official record
Conditions
Obesity, Smoking Cessation, Bariatric Surgery Patients
Interventions
Naltrexone hydrochloride, Bupropion Hydrochloride Extended-release, Cognitive-Behavioral Therapy
Drug · Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 1 Interventional

Seasonal Affective Depression (SAD) Study

NCT00069459
View directory record Official record
Conditions
Depressive Disorder
Interventions
Extended-release Bupropion Hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
48
States / cities
Anchorage, Alaska • Hamden, Connecticut • Newark, Delaware + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Results available

Effect of Bupropion on Seizure Threshold in Depressed Patients

NCT03126682
View directory record Official record
Conditions
MDD
Interventions
Wellbutrin SR 300Mg Extended-Release Tablet
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2019 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 3 Interventional

Attention-Deficit Hyperactivity Disorder (ADHD) Study With Adults

NCT00048360
View directory record Official record
Conditions
Attention Deficit Disorder
Interventions
Extended-release bupropion hydrochloride
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
21
States / cities
Phoenix, Arizona • Chula Vista, California • Lafayette, California + 18 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetic Study of Bupropion Hydrochloride Products With Different Release Patterns

NCT02078180
View directory record Official record
Conditions
Depression
Interventions
generic bupropion
Drug
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 4, 2026, 5:49 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery

NCT02173886
View directory record Official record
Conditions
Roux en Y Gastric Bypass
Interventions
Bupropion SR and XL
Drug
Lead sponsor
North Dakota State University
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 4, 2026, 5:49 AM EDT